MiniMed Expands European Diabetes Portfolio with Abbott Instinct Sensors

The rollout, beginning this month, marks a shift toward greater flexibility for European patients. The MiniMed 780G, an automated insulin delivery system, utilizes Meal Detection technology to mitigate blood glucose spikes, particularly when users miss a bolus or miscalculate carbohydrate intake. Clinical data published in Diabetes Technology & Therapeutics indicates that glycemic outcomes remain consistent when using the new Instinct sensor compared to previous models.

For those managing their condition through multiple daily injections, the MiniMed Go system integrates real-time continuous glucose monitoring with the InPen smart insulin pen. This configuration provides users with actionable alerts and dose tracking through a single mobile application, addressing the fragmented nature of manual diabetes care. According to Que Dallara, CEO of MiniMed, the integration is designed to reduce the mental burden of daily management by providing technology that adapts to individual lifestyles. The sensors have received CE mark approval, allowing for their gradual expansion across select European markets following the initial launch phase.